AU2002211566A1 - Method for identifying increased risk of death from community acquired pneumonia - Google Patents

Method for identifying increased risk of death from community acquired pneumonia

Info

Publication number
AU2002211566A1
AU2002211566A1 AU2002211566A AU1156602A AU2002211566A1 AU 2002211566 A1 AU2002211566 A1 AU 2002211566A1 AU 2002211566 A AU2002211566 A AU 2002211566A AU 1156602 A AU1156602 A AU 1156602A AU 2002211566 A1 AU2002211566 A1 AU 2002211566A1
Authority
AU
Australia
Prior art keywords
death
increased risk
acquired pneumonia
community acquired
identifying increased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211566A
Inventor
Grant W. Waterer
Richard G. Wunderink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002211566A1 publication Critical patent/AU2002211566A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
AU2002211566A 2000-10-10 2001-10-10 Method for identifying increased risk of death from community acquired pneumonia Abandoned AU2002211566A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23913300P 2000-10-10 2000-10-10
US60239133 2000-10-10
PCT/US2001/031577 WO2002031197A1 (en) 2000-10-10 2001-10-10 Method for identifying increased risk of death from community acquired pneumonia

Publications (1)

Publication Number Publication Date
AU2002211566A1 true AU2002211566A1 (en) 2002-04-22

Family

ID=22900752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211566A Abandoned AU2002211566A1 (en) 2000-10-10 2001-10-10 Method for identifying increased risk of death from community acquired pneumonia

Country Status (3)

Country Link
US (1) US6866999B2 (en)
AU (1) AU2002211566A1 (en)
WO (1) WO2002031197A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112485448B (en) * 2020-11-20 2021-08-24 浙江大学 Application of NMI protein as biological target in preparation of adult community acquired pneumonia severity and prognosis evaluation kit

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200313A (en) * 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
ES8706823A1 (en) 1985-03-28 1987-06-16 Cetus Corp Process for amplifying, detecting, and/or cloning nucleic acid sequences.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1998035012A2 (en) * 1997-02-12 1998-08-13 Chan Eugene Y Methods and products for analyzing polymers
JP2002540801A (en) * 1999-04-02 2002-12-03 インタールーキン ジェネティックス インク Predicting the risk of interstitial lung disease
AU2001222818A1 (en) * 2000-10-10 2002-04-22 Genomics Collaborative, Inc. Method of diagnosing and treating increased risk of death from community-acquired pneumonia associated with the allele of the tnfalpha-238 polymorphism

Also Published As

Publication number Publication date
US20020086016A1 (en) 2002-07-04
US6866999B2 (en) 2005-03-15
WO2002031197A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2001234608A1 (en) Methods for analysis of gene expression
AU2001240115A1 (en) Method for the preparation of tetrahydrobenzothiepines
AU2002303584A1 (en) Method for identifying comparable instruments
AU4005900A (en) Method for identification of unknown substances
AU2001290685A1 (en) Methods for inhibiting inflammatory disease
AU2002302243A1 (en) Method for determination of co-occurences of attributes
AU2002247183A1 (en) Removal of acids from oils
AU2002216080A1 (en) Method for determining competing risks
AU2001271841A1 (en) Methods for identifying combinations of drugs
AU2001232354A1 (en) Method for managing physical distribution of merchandise
AU2002361357A1 (en) Method for monosulphonylation of an aminobenzofuran compound
EP1275633A3 (en) Method for decomposition of Michael type adduct
AU2002222618A1 (en) Method of analyzing gene expression
AU2000248557A1 (en) Method of removing microbial contamination
AU2001278135A1 (en) Method of identifying immunosuppressive agents
AU2001287268A1 (en) Method of identifying inhibitors of tie-2
AU2001213451A1 (en) Method for preparation of polycarbonates
AU2002211566A1 (en) Method for identifying increased risk of death from community acquired pneumonia
AU2002214954A1 (en) Process for the preparation of phenylphenol compounds
AU4151800A (en) Method for extracting business rules
AU2001258718A1 (en) An improved process for the preparation of quinolone derivatives
AU2002210816A1 (en) Process for preparation of beta-phenethylamine derivative
AU2002220757A1 (en) Method for obtaining azaerythromycin
AU2002351532A1 (en) Method of sampling
AU2001246862A1 (en) Method of detecting cancer